|
|
 |
This conference will be simultaneously translated 此会议将会有中英同声翻译
Welcome to the 7th China Pharmaceutical R&D Summit
The must-attend event for the life sciences industry recognized and endorsed by top-level executives of the China’s pharma and biotech companies brings the knowledge, the network and business partnering a notch higher.
With proven attendance from top-level executives from China’s major pharma and biotech companies, we bring over 400 relevant decision makers from Asia and internationally gathering to discuss innovation in Pharma R&D and emerging models of development. Hear from experts, meet potential collaborators and gather insights to re-align your own R&D strategy – only at China Pharmaceutical R&D Summit
Featuring Presentations from:
|
Global Pharma 来自全球制药行业的演讲者 |
|
|
Joe McCracken, Global Head of Business
Development and Licensing, Roche, USA
Helmut Haning, Senior Vice President, Head of Global Innovation Sourcing, Bayer Schering Pharma, Germany
Ling Chen, Vice President of R&D China Operations, GlaxoSmithKline
Stevan W Djuric, Senior Director, Global Pharmaceutical Research and Development, Abbott, USA |
Stevan W Djuric, Senior Director, Global Pharmaceutical Research and Development, Abbott, USA
Frank Shen, Vice President Global Data
Management and Statistics, Global Pharmaceutical R&D, Abbott, USA
Mary Haak-Frendscho, President and Chief Scientific Officer, Takeda San Francisco, USA |
|
Thought Leaders from Academia 学术界和生物技术领域享誉世界的思想领导者 |
|
|
Susan Windham-Bannister, President, Massachusetts Life Science Center, USA
Ralf Altmeyer, Director General, Institut Pasteur, China
Hongbin Sun, Director, Center for Drug Discovery, China Pharmaceutical University |
Kewei Wang, Professor and Chair, Department of Molecular and Cellular Pharmacology, Peking University School of Pharmaceutical Sciences, China
Yuqiang Wang, Professor and Dean, Jinan
University College of Pharmacy, China |
|
PLUS Regional Industry Experts 以及区域行业专家 |
|
|
Herng-Der Chern, Distinguished Research Fellow, Center for Drug Evaluation, Taiwan
Zhenping Zhu, President & Chief Executive Officer, Kadmon China
John Oyler, Chief Executive Officer and Founder, Beigene, China
Vijay Karwal, Managing Director, Royal Bank of Scotland, Hong Kong
Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, Singapore |
Satheeshkumar Sriharan, Chief Representative / Country Head-China, Dr Reddy’s Laboratories, China
Li Chen, President & Chief Executive Officer, Hua Medicine, China
Jonathan Wang, Partner, Legend Capital, China
Youling Wu, Chief Executive Officer, ZheJiang Teruisi, China |
And more...
|
| - |
China Pharma R&D is BIGGER and better in its 7th year,
co-located with
 and  |
| - |
Hard-hitting, power packed discussions in a revamped programme format |
| - |
Fresh insights from never-before heard speakers from industry and academia |
| - |
First Asian Pharma Idol Innovati on Showcase |
| - |
Regulatory Country Snapshots featuring key Asian markets |
| - |
High Impact Investment and Funding discussions from leading VCs and big pharma |
| - |
Unparalleled learning and targeted networkingin the longest running international pharma R&D event in the region |
|
| - |
步入第七个年头，中国药物研发峰会规模更 大、内容更丰富，与和
在同一地点举办 |
| - |
采用全新会议形式，讨论内容深入，各路专家云集 |
| - |
业界和学术界此前从未出现过的演讲者带来新鲜观点 |
| - |
首届亚洲制药偶像创新展示 |
| - |
重要亚洲市场监管国家/地区概况 |
| - |
著名风险投资公司探讨高影响力的投资和资助 |
| - |
区域内持续时间最长的国际药物研发大会，提 |
|
|
|
|
|
|
|
Pre-Conference Workshop A • 23 April 2012
U.S. Market Entry:
A Regulatory, Legal, and Medical
Communication Perspective |
Post-Conference Workshop B • 26 April 2012
Turning Strategies into Tactical Plans to Optimize Market Entry – Balancing Commercial, Regulatory and Investments to Deliver Successful Business Models |
|
|
|
|
|
|
| |
|
 |
AGENDA AT A GLANCE |
|
| |
|
AM |
LUNCH |
PM |
MON
23 APRIL |
Pre-Conference Workshops:
US Market Entry: A Regulatory, Legal, and Medical Communication Perspective (Full Day)
Expression Systems for Antibody and Vaccine Biomanufacturing (Full Day) |
LUNCH,
AM & PM BREAKS |
US Market Entry: A Regulatory, Legal, and Medical Communication Perspective
Expression Systems for Antibody and Vaccine Biomanufacturing
Meet the Speakers Reception (by Invitation only) |
TUE
24 APRIL |
China Pharma R&D, Vaccines & Biosimilars
JOINT PLENARY SESSION
Global and Regional Keynote Presentations
On Pharma R&D |
EXHIBITION & POSTER SESSION
DISCUSSION DEN
CRO Clinic / Onsite “Lab’ & Demonstrations
China Technology & Services Pavilion |
China Pharmaceutical R&D Summit
• Regulatory Snapshots
• R&D Leaders Panel
• Investment & Funding
• ‘Pharma Idol’: Innovation
Showcase
• CXO Panel Discussion
• Funding for Innovation |
Discussion Den:
In depth roundtable discussions on Regulatory and
Collaborations in Key Asian Countries
NETWORKING RECEPTION
EVENING DINNER (Optional) |
Vaccines China
• Market Trends & Outlook
• Vaccines Quality Control &
Compliance
• Novel Development of Vaccines
• Regulatory Snapshots
• Visionary Panel Discussion |
Biosimilars Asia
• Market Entry & Opportunities
• Commercial Viability
• Regulatory Snapshots
• Visionary Panel Discussion |
|
WED 25 APRIL |
China Pharmaceutical R&D Summit
• Drug Development & Partnering Strategies
• Emerging Business Models< in R&D
• Discovery & Early Stage Devt
• Role of Academia in Drug
Discovery & Development |
Vaccines China
• Novel Vaccine Candidates for Tropical Diseases
• Research and Clinical Updates for EV71 vaccines |
Biosimilars Asia
• External Collaborations & Commercial Value
• Breaking into Protectionist Markets
• Intellectual Property Legal Debate |
|
China Pharmaceutical R&D
Summit
• ‘Pharma Idol’: Innovation Showcase and Awarding
• Clinical Development & Partnerships in Asia
• Future Opportunities in Biosimilars & Biobetters
• Closing Visionary Panel Discussion |
Vaccines China
• Innovations & Technological Advancements
• Future Opportunities for Sustainable Return on Investment |
Biosimilars Asia
• Mad about mAbs
• Developing Biosimilars & Biobetters
• Winning Buy-in
• Closing Panel Debate |
|
THU 26 APRIL |
Post-Conference Workshops:
Next Generation of Vaccine Facilities
with Focus on Design & Containment
Turning Strategies into Tactical
Plans to Optimize Market Entry –
Balancing Commercial, Regulatory
and Investments to Deliver Successful
Business Models |
|
|
|
.jpg)
